

Quarterly Report

March 31, 2009



Letter to our Stockholders

Dear Stockholders,

In spite of the considerable turbulence on the markets, we have succeeded in starting the year 2009 very positively. We are not only able to show greatly increased business figures, but also look to very attractive increases in orders and successes in implementing our projects. This is a result, with which we are very satisfied for the start of the year and which demonstrates the solidity of our business model.

2

NEXUS had numerous software operation startups at new customers in Germany and other countries in the first months of 2009. At the same time, we have worked on developing our software modules further and integrating the companies and technologies acquired over the past years into our Group and products.

Our larger international projects are real highlights, which have presented us with considerable challenges over the past months. We started operation with our complete software program in three regions in Saudi Arabia, put area modules can-ton-overlapping into operation for St. Gallen (CH), and started productive operation of Phase I in the Aarau Canton Hospital (CH). We were also able to start „real operation“ of our software for very important customers in Germany in the Berlin Heart Center, Neunkirchen Hospital and APZ Königslutter. On the side of development projects, we were very involved in the projects of new financial accounting, new care planning, the referral portal and intensive care module, which resulted and is resulting in forcing us to use our development resources to the limit.

The restructuring of our business in the areas „Clinical Information Systems“, „Diagnostic Information Systems“ and „IT Services“ is targeting the consistent integration of the companies acquired over the past years. It shows at the same time that our organization is pursuing the strategy of parallel development of independent hospital and diagnostic information systems on the basis of a uniform technology. We see a great strategic advantage for NEXUS there. In both areas, the hospital and the diagnostic product lines, we have invested parallel without committing the error of uncompromising standardization.

Highlights Q1 - 2009 Business development

- + Strongly increasing business figures
- + Integration of the radiooncology solutions into our own sales activities
- + „Finale phase“ in many large projects
- + Many operation startups and new projects in the 1st quarter

The cited topics show that NEXUS concluded a substantial program of work during the first months of 2009, which is oriented completely to growth, innovation and revenue optimization. Especially now against the background of the problems in the overall economy, we consider this strategy appropriate to distinguish us from our competitors in the long term.

We are still facing substantial challenges in all areas of our work, which we have to meet simultaneously: providing innovations on time, the smoothest possible operation startup of new projects and consistent integration of new companies and technologies. These are all great challenges, which we have to meet as a whole. NEXUS is well equipped for these tasks, and it has also proven in the past that it can master them.

We also see proof of this in the business figures of the first quarter. We have again succeeded in increasing all key figures substantially by two-figure amounts and consequently also continued the positive development of our company for the ninth year in a row.

Sales increased from EUR 7.4 million to EUR 9.5 million (28.3%) during the first three months. As expected, the Healthcare Software Division developed strongly and recorded sales of 8.4 million euros with an increase of 31% following 6.4 million euros in the first quarter 2008.

The operating result before taxes also developed clearly positively in the first quarter. The result before taxes of KEUR 549 improved significantly by approx. 43% following KEUR 383 in the previous year.

After taxes, there was also a substantial improvement in the result. Following KEUR 378 in the previous year, a result of KEUR 460 (+22%) was achieved in the first quarter 2009. The operative cash flow is certainly also to be emphasized here.

The operative cash flow increased very considerably from KEUR 1.671 in Q1-2008 to KEUR 3,047. This is especially due to the improved result and higher amounts of reserves.

The balance sheet relations have in part changed considerably corresponding to 31 December 2008 in the areas of accounts receivables, liquid funds and other accounts payable. Accounts receivable increased greatly analog to business development and amounted to approx. 12.5 million euros on 31 March 2009. At the same time, liquid funds including securities increased by approx. 1.5 million euros to approx. 11.0 million euros. Other accounts payable increased to 6.9 million euros due to increased reserves.

The very strong first quarter 2009 makes us confident that we can continue to pursue the course of the past years successfully and maybe even progress faster. In spite of the difficult environment, we are well positioned in almost all company areas and have substantial potential for further increases.

Despite this, we still have to act prudently and keep an eye on profitability and our cash flow. The risks and uncertainties in the market are considerable, and it is currently difficult to predict the consequences that could result for NEXUS. The in part problematic situation of some of our competitors demonstrates this danger.

However, we are resolutely determined – and convinced of this today more than ever – to continue to orient and develop our company, so that we are also among those at the top internationally. This is a challenge and an incentive that drives us forward.

Sincerely



Dr. Ingo Behrendt
CEO - NEXUS AG




Substantial Growth

in the 1st Quarter

NEXUS Group sales increased from KEUR 7,412 to KEUR 9,512 (+28.3%) in the first six three months of the year 2009. The increase was again especially substantial in the „Healthcare Software“ segment. Sales increased **by 31.4% from KEUR 6,383 to KEUR 8,390** compared to the same period of the previous year. Sales in the area of „Healthcare Service“ increased by **9% to KEUR 1,122 following KEUR 1,029** in the period of the previous year. Sales by Medos AG are consolidated in these figures.

4

Sales in other countries increased to KEUR 3,600 from KEUR 2,512 in the previous year. Sales increased especially strongly in Switzerland and Arab countries. As a result, **the share of sales outside of Germany was 37.8% following 34.2% in the previous year.** This value demonstrates the high regard for our systems outside of Germany too.



Highlights Q1 - 2009 Group sales and Result

- + 28.3% sales increase in first quarter 2009 from KEUR 7,412 (Q1 2008) to KEUR 9,512
- + 31.4% sales increase from KEUR 6,383 (Q1 2008) to KEUR 8,390 in the Healthcare Software area
- + Strong increase in result before taxes (+43.3%)
- + Strongly positive operative cash flow (+82.4 %)
- + 33.8% increase in EBITDA from KEUR 1,268 (Q1 2008) to KEUR 1,697


| Sales by regions | 01/01/ - 03/31/08 | 01/01/ - 03/31/09 | Δ in % |
|---------------------|----------------------|----------------------|-------------|
| | KEUR | KEUR | |
| Germany | 4,900 | 5,913 | 20.7 |
| Switzerland | 1,869 | 2,215 | 18.5 |
| Austria | 255 | 257 | 0.8 |
| Italy | 28 | 28 | 0 |
| Rest of world / USA | 360 | 1,099 | 205.6 |
| Total | 7,412 | 9,512 | 28.3 |

| Sales by divisions | 01/01/ - 03/31/08 | 01/01/ - 03/31/09 | Δ in % |
|---------------------|----------------------|----------------------|-------------|
| | KEUR | KEUR | |
| Healthcare Software | 6,383 | 8,390 | 31.4 |
| Healthcare Service | 1,029 | 1,122 | 9.0 |
| Total | 7,412 | 9,512 | 28.3 |

Results in the First Quarter 2009

The positive development of the operating result of last year continued during the reporting period. The Group result increased greatly by 21.8% to KEUR 460 (previous year: KEUR 378), and the result before taxes improved by 43,3% to KEUR 549 (previous year: KEUR 383).

The **EBITDA** increased by KEUR 429 in the first quarter 2009 (previous year: KEUR 1,268) to **KEUR 1,697** (+33.8%). The very good development of results in the first quarter are mainly due to the fact that the services provided in advance for large projects and the expenditures for company integration could be reduced gradually. In addition, the share of recurring revenues is increasing very substantially.




5

The operative cash flow developed correspondingly well. Compared to the previous year, it increased by KEUR 1,376 from KEUR 1,671 to KEUR 3,047 (+82.4%). Liquid funds increased correspondingly in the first quarter compared to the end of the year 2008 and amounted to 11.0 million euros following 9.5 million euros on 31 December 2008.

The „**Healthcare Software**“ segment achieved a **result of KEUR 341** in the first three months 2009 following KEUR 355 in the same period of the previous year. The „**Healthcare Service**“ segment was able to close at **KEUR 119** clearly higher than the level of the previous year (KEUR 23).

The number of employees increased compared to the previous year by 30 to 341 employees from now on. The buildup came basically from the „Healthcare Software“ segment.




Innovation: NEXUS / RADIOONKOLOGIE - Modern Solution for Radiotherapy

Software radiooncology is a strategic topic for NEXUS. We have been developing and selling radiooncology solutions internationally since 1999. We have recently been doing this together with our partner Nucletron B.V., Holland. NEXUS supports more than 80 radiooncology customers in eight countries directly and indirectly.


As of 1 April 2009, NEXUS AG and Nucletron B.V. concluded an agreement for the product Oncentra Information Management (OIM) and put the future of the product into the sole hands of NEXUS. We are again going to take product responsibility for NEXUS / OIM and be responsible for its further development and marketing in the future. With this, we are expanding our existing activities of many years in the radiotherapy market and will have the chance of supporting customers directly and more intensively in the future.

We want to use these changes to increase customer service and the speed of innovation of all aspects of NEXUS / OIM. The product NEXUS / OIM is to focus more strongly again on the market of radiooncologists in the future. NEXUS / OIM is considered a very flexible and highly innovative solution for helping radiooncology wards to optimize their process, coordinate schedules and appointments and provide comprehensive documentation of patients – and all of this completely integrated into the medical technology of radiotherapy. Today, we work together with all record and verifying systems on the market as well as commonly used planning systems and consequently are excellently suited to take the position of an independent premium supplier in this segment.

Our customers (e.g., ARTI Arnhem, Innsbruck University and Oslo University) rely on the flexible and intuitive structure of NEXUS / OIM in many large European radiotherapy wards. We are already considered an independent, modern and flexible solution on the market today, which is especially oriented to innovative customers



NEXUS solution for radiooncologists: intuitive user-prompting for supporting processes.



This is an image that we want to expand in the future: enhance our products with new functions and support our customer more intensively. For example, the next release will already be provided with the Vista-based NEXUS interface and with numerous additional functions, e.g., a chart and an integrated laboratory view.

NEXUS in the Environment of the Financial and Health Markets



The price of NEXUS stocks rose progressively at the beginning of the year from originally € 1.56 to approx. € 2.00 at the end of January. This was followed by a consolidation phase lasting several weeks with an upward trend until the price increased again to more than € 2.25 at the end of February. In March, there was a lateral trend with occasional „runaway values“ in the range of € 2.00 to € 2.22 until the price rose again the last third of the month to € 2.35 shortly before publication of the year-end report 2008. In April, the price increased further to the interim year high of € 2.50 until it consolidated at its current value of approx. € 2.35 at the turn of the month.

Finance- and Event schedule 2009 (status quo: May `09)

Finance schedule

| | |
|---|------------------|
| General stockholders meeting, Stuttgart (D) | June 15th |
| Half-year Report | August 17th |
| German equity forum, Frankfurt (D) | 09 - 11 November |
| Quarterly Report - third quarter | November 9th |

Event and trade fair schedule

| | |
|---------------------------------------|-------------------|
| Deutscher Röntgenkongress, Berlin (D) | 20 - 23 May |
| Think Tank QM, Berlin (D) | Mai 28th |
| eHealthcare Congress, Nottwil (CH) | 23 - 24 September |
| KTQ-Forum, Berlin (D) | November 2nd |
| MEDICA, Düsseldorf (D) | 18 - 21 November |
| DGPPN, Berlin (D) | 25 - 28 November |

Decisions for NEXUS-solutions 2009

- + HELIOS Klinikum, Aue
- + Helsingpark-Clinic, Augsburg
- + Edith Stein Fachklinik, Bad Bergzabern
- + Werner-Wicker-Klinik, Bad Wildungen
- + Krankenhaus St. Marienwörth, Bad Kreuznach
- + Klinikum Reinkenheide, Bremerhaven
- + BG Unfallklinik, Frankfurt (Main)
- + Pathologische Praxis, Friedrichshafen
- + EuromedClinic, Fürth
- + Alfried Krupp Krankenhaus, Essen
- + Universitätsklinikum, Halle (Saale)
- + St. Franziskus-Hospital, Münster
- + Allgemeines Krankenhaus, Viersen
- + Dr.-Horst-Schmidt-Kliniken, Wiesbaden
- + Hospital Virga Jesse, Hasselt (BE)
- + Kantonsspital Winterthur, Winterthur (CH)
- + Hospital Rio Hortega, Valladolid (ES)

NEXUS Group information and Outlook

Directors Holdings

The Director's Holdings of the supervisory board and the executive board were as follows on March 31, 2009 in comparison to the previous year:

Outlook

The first quarter was very positive. Sales increases of 28% and an increase of the result before taxes of 43% are very pleasing news. The same applies to the EBITDA, which is absolutely noteworthy for the first quarter at € 1.7 million. These results are not only notable against the background of the difficult environment, but also against the background of the continual development of the past years. In spite of good increase rates in the previous years, we have been able to maintain this trend till now.

However, we are faced with substantial challenges over the next months as in every growth model. We have to complete development projects, which are critical for our future development. We have to finish large customer projects, have them approved by customers and get them paid, projects which are also critical for our reputation in the respective markets. And we have to continue integration of our organization and orient processes more to customers.

Only mastery of these challenges will make it possible to continue the development of the past years. To do this, we have to make corresponding efforts and have the determination to look forward even in difficult economic times. These are challenges, which we are glad to face. We are enthusiastic about the dynamics of our market and our development and believe in our product portfolio and our staff, who are determined to achieve dynamic growth and earning power in the future too.

ACCOUNTING AND VALUATION METHODS

This interim report from the NEXUS Group of March 31, 2009 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The regulations of IAS 34 have been observed in the interim report of March 31, 2009. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2008. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2008.

The report has not been audited.

| Directors Holdings | Numbers of stocks owned | Numbers of options |
|---|-------------------------|---------------------|
| Supervisory Board | | |
| Dr. jur. Hans-Joachim König | 81,099 | 0 |
| | Previous year: 81,099 | Previous year: 0 |
| Prof. Dr. Alexander Pocsay | 0 | 0 |
| | Previous year: 0 | Previous year: 0 |
| Ronny Dransfeld | 0 | 0 |
| | Previous year: 0 | Previous year: 0 |
| Prof. Dr. Ulrich Krystek | 0 | 0 |
| | Previous year: 0 | Previous year: 0 |
| Dipl.-Betriebsw. (FH) Wolfgang Dörflinger | 0 | 0 |
| | Previous year: 0 | Previous year: 0 |
| Dr. Dietmar Kubis | 0 | 0 |
| | Previous year: 0 | Previous year: 0 |
| Executive Board | | |
| Dr. Ingo Behrendt (MBA) | 112,000 | 325,000 |
| | Prev. year: 112,000 | Prev. year: 325,000 |
| Dipl.-Betriebsw. (FH) Ralf Heilig (MBA) | 129,350 | 60,000 |
| | Prev. year: 129,350 | Prev. year: 60,000 |
| Dipl.-Ing. (FH) Edgar Kuner | 264,051 | 37,000 |
| | Prev. year: 264,051 | Prev. year: 37,000 |

Facts and Figures

Group P+L Account as of 03/31/2009 and 03/31/2008 (IFRS)

| CONSOLIDATED PROFIT AND LOSS ACCOUNT | 01/01/ - 03/31/08 | 01/01/ - 03/31/09 | |
|--|--------------------------------|----------------------|-----|
| | KEUR | KEUR | |
| 1. Revenue | 7,412 | 9,512 | |
| 2. Increase / decrease in finished goods and work in progress | -33 | -25 | |
| 3. Other capitalized company work | 946 | 1,012 | |
| 4. Other operating income | 336 | 381 | |
| 5. Cost of materials | 1,470 | 2,131 | |
| a) Cost of raw materials and supplies | 1,073 | 1,528 | |
| b) Cost for purchased services | 397 | 603 | |
| 6. Personnel expenses | 4,688 | 5,221 | |
| a) Wages and salaries | 4,003 | 4,450 | |
| b) Social costs | 685 | 771 | |
| 7. Depreciation and amortization of fixed intangible and tangible assets | 1,084 | 1,280 | |
| 8. Other operating expenses | 1,237 | 1,829 | |
| a) Cost of operation | 411 | 538 | |
| b) Cost of distribution | 301 | 374 | |
| c) Cost of administration | 485 | 524 | |
| d) Other expenses | 40 | 393 | |
| 9. Other taxes | 3 | 2 | |
| OPERATING INCOME | 178 | 417 | |
| 10. Expenses from associated companies | 3 | - | |
| 11. Other interest and similar income | 235 | 142 | |
| 12. Revenue from associated companies | 33 | 10 | |
| PROFIT BEFORE TAX | 383 | 549 | |
| 13. Income taxes | -5 | -89 | |
| ANNUAL NET PROFIT | 378 | 460 | |
| | Are attributable to: | | |
| | Stockholders of parent company | 357 | 434 |
| | Minority interest | 21 | 26 |
| Weighted average of issued shares (in thousands) | 13,805 | 13,805 | |
| RESULT PER SHARE IN EUR (DILUTED AND UNDILUTED) | 0.03 | 0.03 | |

Facts and Figures

Balance sheet as of 03/31/2009 and 12/31/2008 (IFRS)

10

| BALANCE SHEET AS OF 03/31/2009 (IFRS) | 12/31/2008 | 03/31/2009 |
|---|-------------------|-------------------|
| ASSETS | | |
| | KEUR | KEUR |
| LONG-TERM CAPITAL | | |
| I. Intangible assets | | |
| 1. Concessions / licenses | 525 | 520 |
| 2. Goodwill | 11,636 | 11,809 |
| 3. Development costs | 9,532 | 9,628 |
| 4. Customer Base / Technology | 5,203 | 5,103 |
| II. Property, plant and equipment | | |
| 1. Tenant installations | 60 | 20 |
| 2. Other equipment, factory and office equipment | 1,136 | 1,081 |
| III. Financial assets | | |
| 1. Investments in associates | 101 | 50 |
| 2. Other loans | 112 | 122 |
| IV. Deferred taxes | 3,965 | 3,941 |
| TOTAL LONG-TERM CAPITAL | 32,270 | 32,274 |
| SHORT-TERM CAPITAL | | |
| I. Inventories | | |
| 1. Raw materials and supplies | 48 | 22 |
| 2. Work in progress | 103 | 78 |
| 3. Finished goods | 128 | 322 |
| II. Receivables and other assets | | |
| 1. Trade receivables | 9,489 | 12,454 |
| 2. Receivables from associated companies | 6 | 6 |
| 3. The gross amount due to customers for projects as an asset | 875 | 0 |
| 4. Tags refund claims | 450 | 279 |
| 5. Other assets | 2,414 | 3,070 |
| III. Derivative financial instruments | 129 | 77 |
| IV. Securities | 5,319 | 3,909 |
| V. Cash and cash equivalents | 4,141 | 7,138 |
| TOTAL SHORT-TERM CAPITAL | 23,102 | 27,353 |
| TOTAL ASSETS | 55,372 | 59,629 |

Facts and Figures

Balance sheet as of 03/31/2009 and 12/31/2008 (IFRS)

| BALANCE SHEET AS OF 03/31/2009 (IFRS) EQUITY AND LIABILITIES | 03/31/2008 | 03/31/2009 |
|--|-------------------|-------------------|
| | KEUR | KEUR |
| EQUITY | | |
| I. Subscribed capital | 13,805 | 13,805 |
| II. Capital reserve | 39,483 | 39,497 |
| III. Other reserves | - | - |
| IV. Equity capital difference from currency translation | 59 | 25 |
| V. Valuation reserve for financial instruments | -999 | -1,055 |
| VI. Reserve for pensions | -72 | -68 |
| VII. Loss carry-forward | -9,503 | -8,015 |
| VIII. Annual net profit | 1,488 | 434 |
| IX. Own Shares | -26 | -26 |
| EQUITY CAPITAL ATTRIBUTABLE TO STOCKHOLDERS OF THE PARENT COMPANY | 44,235 | 44,597 |
| Minority interest | 259 | 285 |
| TOTAL EQUITY | 44,494 | 44,882 |
| LONG-TERM LIABILITIES | | |
| I. Pension provisions | 534 | 531 |
| II. Other provisions | 2,112 | 2,034 |
| TOTAL LONG-TERM LIABILITIES | 2,646 | 2,565 |
| SHORT-TERM LIABILITIES | | |
| I. Tax provisions | 653 | 1,149 |
| II. Other provisions | 111 | 28 |
| III. Bank loans | 947 | 576 |
| IV. Received payments or orders | 2,431 | 2,795 |
| V. Trade accounts payable | - | 8 |
| VI. Liabilities with associated companies | 1,016 | 681 |
| VII. Other liabilities | 3,074 | 6,945 |
| TOTAL SHORT-TERM LIABILITIES | 8,232 | 12,182 |
| TOTAL EQUITY AND LIABILITIES | 55,372 | 59,629 |

| CASH FLOW | 2008 | 2009 |
|---|---------------|--------------|
| | KEUR | KEUR |
| 1. CASH FLOW FROM OPERATING ACTIVITIES | | |
| Profit before minority interest and before tax | 378 | 549 |
| Depreciation and amortization of intangible assets and plant, equipment and other fixed assets | 1,084 | 1,280 |
| Other expenses / income with no impact on cash | 111 | -113 |
| Profit / loss from disposal of long term capital | 0 | 0 |
| Profit / loss from disposal of securities | 2 | 18 |
| Increase / decrease in inventories | 25 | -143 |
| Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities | -1,657 | -2,744 |
| Changes in provision not included in equity | -144 | 497 |
| Increase / decrease in trade accounts payable and other liabilities that cannot be allocated to investing or financing activities | 1,842 | 3,429 |
| Interest paid | -32 | -10 |
| Interest payments received | 152 | 113 |
| Income taxes paid | -96 | -61 |
| Income taxes received | 6 | 232 |
| | 1,671 | 3,047 |
| 2. CASH FLOW FROM FINANCING ACTIVITIES | | |
| Cash paid for investments in property, plant and equipment / intangible assets | -1,351 | -1,309 |
| Purchase of subsidiaries after deduction of acquired payment means | 0 | 0 |
| Cash received from disposal of securities | 299 | 1,281 |
| Cash paid for investments in securities | 0 | 0 |
| | -1,052 | -28 |
| 3. CASH FLOW FROM FINANCING ACTIVITIES | | |
| Cash received for equity | 0 | 0 |
| Amount paid out for redeeming loans | -133 | -83 |
| Purchase common shares | 0 | 0 |
| | -133 | -83 |
| 4. CASH AND CASH EQUIVALENTS AT END OF FISCAL YEAR | | |
| Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3) | 486 | 2,936 |
| Change in currency translation adjustment | 0 | 33 |
| Cash and cash equivalents at beginning of fiscal year | 2,390 | 4,141 |
| | 2,876 | 7,110 |
| 5. COMPOSITION OF CASH AND CASH EQUIVALENTS | | |
| Cash on hand | 2,928 | 7,138 |
| Bank liabilities due on demand | -52 | -28 |
| | 2,876 | 7,110 |

Facts and Figures Development of Group Equity as of 03/31/2009 and 03/31/2008 (IFRS)

| DEVELOPMENT OF GROUP EQUITY | SUBSCRIBED CAPITAL | CAPITAL RESERVES | OTHER PROVISIONS | EQUITY DIFFERENCE FROM CURRENCY CONVERSION | RESERVE FOR FINANCIAL INSTRUMENTS | RESERVE FOR PENSIONS | CONSOLIDATED LOSS CARRY FORWARD | CONSOLIDATED DEFICIT / PROFIT | OWN SHARES | EQUITY CAP , ATTRIBUTABLE TO STOCKH, OF PARENT COMPANY | MINORITY INTEREST | TOTAL EQUITY | AUTHORIZED CAPITAL |
|---|--------------------|------------------|------------------|--|-----------------------------------|----------------------|---------------------------------|-------------------------------|------------|--|-------------------|--------------|--------------------|
| | KEUR | KEUR | | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR | KEUR |
| CONSOLIDATED EQUITY AS OF 31 DECEMBER 2006 | 13,805 | 39,372 | 0 | 10 | -383 | -89 | -10,666 | 1,163 | -26 | 43,186 | 320 | 43,506 | 6,860 |
| Transfer of 2006 consolidated loss to consolidated loss carry-forward | | | | | | | 1,163 | -1,163 | | 0 | | 0 | |
| Total income entered directly in equity capital | | | | 111 | -296 | 14 | | | | -171 | | -171 | |
| Profit before tax 03/31/2007 | | | | | | | | 357 | | 357 | 21 | 378 | |
| OVERALL RESULT OF THE PERIOD | 0 | 0 | 0 | 111 | -296 | 14 | 0 | 357 | | 186 | 21 | 207 | |
| Edition of equity options to employees | | | | | | | | | | 0 | | 0 | |
| Stock-based payment | | 29 | | | | | | | | 29 | | 29 | |
| CONSOLIDATED EQUITY AS OF 31 MARCH 2007 | 13,805 | 39,401 | 0 | 121 | -679 | -75 | -9,503 | 357 | -26 | 43,401 | 341 | 43,742 | 6,860 |
| CONSOLIDATED EQUITY AS OF 31 DECEMBER 2007 | 13,805 | 39,483 | 0 | 59 | -999 | -72 | -9,503 | 1,488 | -26 | 44,235 | 259 | 44,494 | 6,860 |
| Profit before tax 2007 entered directly in accumulated deficit | | | | | | | 1,488 | -1,488 | | 0 | | 0 | |
| Total income entered directly in equity capital | | | | -34 | -56 | 4 | | | | -86 | | -86 | |
| Profit before tax 03/31/2008 | | | | | | | | 434 | | 434 | 26 | 460 | |
| OVERALL RESULT OF THE PERIOD | 0 | 0 | 0 | -34 | -56 | 4 | 0 | 434 | | 348 | 26 | 374 | |
| Stock-based payment | | 14 | | | | | | | | 14 | | 14 | |
| CONSOLIDATED EQUITY AS OF 31 MARCH 2008 | 13,805 | 39,497 | 0 | 25 | -1,055 | -68 | -8,015 | 434 | -26 | 44,597 | 285 | 44,882 | 6,860 |

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, May 18th, 2009

NEXUS AG
Executive Board

nexus/ag

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen
Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888
www.nexus-ag.de, info@nexus-ag.de